{"entity":{"id":"paper-navigator-avapritinib-heinrich-lancet-oncol-2020","kind":"paper","name":"NAVIGATOR: avapritinib in advanced PDGFRA D842V-mutant gastrointestinal stromal tumour","aka":[],"tldr":"Avapritinib shrank tumours in almost nine in ten patients with PDGFRA D842V-mutant gastrointestinal stromal tumour, a subtype completely resistant to imatinib and every other kinase inhibitor, and became its first effective treatment.","summary":"Phase 1 dose-escalation and expansion study; this analysis covers 56 patients with PDGFRA D842V-mutant advanced GIST treated with avapritinib at 300 or 400 mg daily.\n\nObjective response was 88 percent (9 percent complete), median duration of response not reached, and 12-month progression-free survival 81 percent; cognitive effects, periorbital oedema and anaemia were the characteristic toxicities, with rare intracranial bleeding.","asOf":"2026-09-17","links":[{"label":"Lancet Oncol 2020","url":"https://doi.org/10.1016/S1470-2045(20)30269-2"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/32615108/"}],"tags":[],"related":[],"cancers":["gist-pdgfra-d842v"],"sections":[],"technologies":[],"targets":[],"drugs":["avapritinib"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":["navigator"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":["lancet-oncology"],"dependsOn":[],"notes":[],"journal":"The Lancet Oncology","year":2020,"doi":"10.1016/S1470-2045(20)30269-2","pmid":"32615108","authors":"Heinrich MC, Jones RL, von Mehren M, et al.","paperType":"observational","findings":["Objective response 88 percent in PDGFRA D842V-mutant GIST.","Twelve-month progression-free survival 81 percent."],"whatItMeans":"Avapritinib 300 mg is the standard first-line treatment for advanced PDGFRA D842V GIST, and mutation testing before starting imatinib is essential to identify these patients.","caveats":["Single-arm; cognitive side effects need monitoring and dose adjustment.","In non-D842V GIST avapritinib was not superior to regorafenib (VOYAGER)."],"changedPractice":true,"participants":56},"route":"/key-papers/paper-navigator-avapritinib-heinrich-lancet-oncol-2020/","neighbours":{"cancer":[{"id":"gist-pdgfra-d842v","kind":"cancer","name":"PDGFRA D842V-mutant GIST","route":"/cancers/gist-pdgfra-d842v/"}],"drug":[{"id":"avapritinib","kind":"drug","name":"Avapritinib","route":"/drugs/avapritinib/"}],"trial":[{"id":"navigator","kind":"trial","name":"NAVIGATOR","route":"/trials/navigator/"}],"journal":[{"id":"lancet-oncology","kind":"journal","name":"The Lancet Oncology","route":"/journals/lancet-oncology/"}]}}